Published in Science on November 20, 2009
Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science (2010) 10.69
Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science (2011) 7.92
Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature (2011) 7.20
Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science (2013) 5.53
Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science (2013) 4.61
Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility. Proc Natl Acad Sci U S A (2009) 3.92
Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity (2012) 3.77
Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature (2014) 3.50
Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1. J Virol (2010) 3.40
HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol Rev (2013) 3.30
Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog (2011) 3.29
A Blueprint for HIV Vaccine Discovery. Cell Host Microbe (2012) 3.27
Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat Struct Mol Biol (2013) 3.11
Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science (2013) 2.95
Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops. Proc Natl Acad Sci U S A (2012) 2.69
Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proc Natl Acad Sci U S A (2010) 2.51
Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr Opin Immunol (2010) 2.47
Immunology and the elusive AIDS vaccine. Nature (2010) 2.26
HIV-1 antiretroviral drug therapy. Cold Spring Harb Perspect Med (2012) 2.18
Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies. J Virol (2014) 2.09
Molecular architecture of the uncleaved HIV-1 envelope glycoprotein trimer. Proc Natl Acad Sci U S A (2013) 2.05
HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation. J Mol Biol (2011) 2.01
Large-scale conformational sampling of proteins using temperature-accelerated molecular dynamics. Proc Natl Acad Sci U S A (2010) 1.97
Few and far between: how HIV may be evading antibody avidity. PLoS Pathog (2010) 1.94
HIV antibodies. Antigen modification regulates competition of broad and narrow neutralizing HIV antibodies. Science (2014) 1.81
Structure of a clade C HIV-1 gp120 bound to CD4 and CD4-induced antibody reveals anti-CD4 polyreactivity. Nat Struct Mol Biol (2010) 1.77
Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies. PLoS Pathog (2012) 1.74
Human anti-HIV-neutralizing antibodies frequently target a conserved epitope essential for viral fitness. J Exp Med (2010) 1.74
Crystal structure of human antibody 2909 reveals conserved features of quaternary structure-specific antibodies that potently neutralize HIV-1. J Virol (2010) 1.70
MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1. J Exp Med (2011) 1.67
Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env. Nat Struct Mol Biol (2015) 1.64
Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1. Cold Spring Harb Perspect Med (2011) 1.58
Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. PLoS Pathog (2011) 1.57
Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies. PLoS Comput Biol (2010) 1.51
The B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian seroconverter. J Virol (2010) 1.49
Contribution of intrinsic reactivity of the HIV-1 envelope glycoproteins to CD4-independent infection and global inhibitor sensitivity. PLoS Pathog (2011) 1.47
Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors. Cell (2015) 1.46
Effects of the I559P gp41 change on the conformation and function of the human immunodeficiency virus (HIV-1) membrane envelope glycoprotein trimer. PLoS One (2015) 1.46
Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies. J Exp Med (2011) 1.46
High-resolution definition of vaccine-elicited B cell responses against the HIV primary receptor binding site. Sci Transl Med (2012) 1.45
Structural insights into key sites of vulnerability on HIV-1 Env and influenza HA. Immunol Rev (2012) 1.44
A V3 loop-dependent gp120 element disrupted by CD4 binding stabilizes the human immunodeficiency virus envelope glycoprotein trimer. J Virol (2010) 1.43
Coevolution Analysis of HIV-1 Envelope Glycoprotein Complex. PLoS One (2015) 1.39
Structural bases of coronavirus attachment to host aminopeptidase N and its inhibition by neutralizing antibodies. PLoS Pathog (2012) 1.34
Vaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesign. Proc Natl Acad Sci U S A (2014) 1.34
Biochemically defined HIV-1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4-binding site. J Biol Chem (2011) 1.32
Structure-based design, synthesis, and characterization of dual hotspot small-molecule HIV-1 entry inhibitors. J Med Chem (2012) 1.29
Progress in the rational design of an AIDS vaccine. Philos Trans R Soc Lond B Biol Sci (2011) 1.28
In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1. J Virol (2010) 1.25
Lessons learned from HIV-1 vaccine trials: new priorities and directions. Nat Immunol (2012) 1.23
HIV-1 envelope glycoprotein structure. Curr Opin Struct Biol (2013) 1.19
Affinity Maturation of a Potent Family of HIV Antibodies Is Primarily Focused on Accommodating or Avoiding Glycans. Immunity (2015) 1.18
A conserved determinant in the V1 loop of HIV-1 modulates the V3 loop to prime low CD4 use and macrophage infection. J Virol (2010) 1.17
CD4-mimetic small molecules sensitize human immunodeficiency virus to vaccine-elicited antibodies. J Virol (2014) 1.12
Development of prophylactic vaccines against HIV-1. Retrovirology (2013) 1.12
Is developing an HIV-1 vaccine possible? Curr Opin HIV AIDS (2010) 1.11
Local conformational stability of HIV-1 gp120 in unliganded and CD4-bound states as defined by amide hydrogen/deuterium exchange. J Virol (2010) 1.11
Residue-level prediction of HIV-1 antibody epitopes based on neutralization of diverse viral strains. J Virol (2013) 1.10
Epitope specificity of human immunodeficiency virus-1 antibody dependent cellular cytotoxicity [ADCC] responses. Curr HIV Res (2013) 1.09
N332-Directed broadly neutralizing antibodies use diverse modes of HIV-1 recognition: inferences from heavy-light chain complementation of function. PLoS One (2013) 1.09
Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design. Nat Struct Mol Biol (2015) 1.07
Llama antibody fragments recognizing various epitopes of the CD4bs neutralize a broad range of HIV-1 subtypes A, B and C. PLoS One (2012) 1.05
Strategies for eliciting HIV-1 inhibitory antibodies. Curr Opin HIV AIDS (2010) 1.05
Immune focusing and enhanced neutralization induced by HIV-1 gp140 chemical cross-linking. J Virol (2013) 1.02
Structural basis for highly effective HIV-1 neutralization by CD4-mimetic miniproteins revealed by 1.5 Å cocrystal structure of gp120 and M48U1. Structure (2013) 1.00
Antigenicity and Immunogenicity in HIV-1 Antibody-Based Vaccine Design. J AIDS Clin Res (2012) 1.00
Single-Chain Soluble BG505.SOSIP gp140 Trimers as Structural and Antigenic Mimics of Mature Closed HIV-1 Env. J Virol (2015) 0.99
Proteolytic processing of the human immunodeficiency virus envelope glycoprotein precursor decreases conformational flexibility. J Virol (2012) 0.99
Structure-based vaccine design in HIV: blind men and the elephant? Curr Pharm Des (2010) 0.99
The changing face of HIV vaccine research. J Int AIDS Soc (2012) 0.97
Broad and potent neutralizing antibody responses elicited in natural HIV-2 infection. J Virol (2011) 0.96
Design of a non-glycosylated outer domain-derived HIV-1 gp120 immunogen that binds to CD4 and induces neutralizing antibodies. J Biol Chem (2010) 0.96
Conformational evaluation of HIV-1 trimeric envelope glycoproteins using a cell-based ELISA assay. J Vis Exp (2014) 0.95
Modeling virus- and antibody-specific factors to predict human immunodeficiency virus neutralization efficiency. Cell Host Microbe (2013) 0.95
Crystal structure of the neutralizing Llama V(HH) D7 and its mode of HIV-1 gp120 interaction. PLoS One (2010) 0.94
Accelerating HIV vaccine development. Nature (2010) 0.93
Straightforward selection of broadly neutralizing single-domain antibodies targeting the conserved CD4 and coreceptor binding sites of HIV-1 gp120. J Virol (2012) 0.93
Rational design and characterization of the novel, broad and potent bispecific HIV-1 neutralizing antibody iMabm36. J Acquir Immune Defic Syndr (2014) 0.92
Stabilizing exposure of conserved epitopes by structure guided insertion of disulfide bond in HIV-1 envelope glycoprotein. PLoS One (2013) 0.91
Engineering, expression, purification, and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins. J Virol (2011) 0.91
Rapid conformational epitope mapping of anti-gp120 antibodies with a designed mutant panel displayed on yeast. J Mol Biol (2012) 0.91
Isolate-specific differences in the conformational dynamics and antigenicity of HIV-1 gp120. J Virol (2013) 0.91
A model of peptide triazole entry inhibitor binding to HIV-1 gp120 and the mechanism of bridging sheet disruption. Biochemistry (2013) 0.90
Epitope mapping of broadly neutralizing HIV-2 human monoclonal antibodies. J Virol (2012) 0.90
Selection of a rare neutralization-resistant variant following passive transfer of convalescent immune plasma in equine infectious anemia virus-challenged SCID horses. J Virol (2010) 0.90
3D visualization of HIV virions by cryoelectron tomography. Methods Enzymol (2010) 0.89
A mechanistic understanding of allosteric immune escape pathways in the HIV-1 envelope glycoprotein. PLoS Comput Biol (2013) 0.88
Tyrosine sulfation in the second variable loop (V2) of HIV-1 gp120 stabilizes V2-V3 interaction and modulates neutralization sensitivity. Proc Natl Acad Sci U S A (2014) 0.87
A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1. PLoS One (2013) 0.87
Neutralization properties of simian immunodeficiency viruses infecting chimpanzees and gorillas. MBio (2015) 0.87
Prime-boost immunization of rabbits with HIV-1 gp120 elicits potent neutralization activity against a primary viral isolate. PLoS One (2013) 0.86
HIV-1 receptor binding site-directed antibodies using a VH1-2 gene segment orthologue are activated by Env trimer immunization. PLoS Pathog (2014) 0.86
HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth. Expert Opin Ther Targets (2015) 0.86
Peptide Triazole Inactivators of HIV-1 Utilize a Conserved Two-Cavity Binding Site at the Junction of the Inner and Outer Domains of Env gp120. J Med Chem (2015) 0.86
Evolution of cross-neutralizing antibody specificities to the CD4-BS and the carbohydrate cloak of the HIV Env in an HIV-1-infected subject. PLoS One (2012) 0.85
Key gp120 Glycans Pose Roadblocks to the Rapid Development of VRC01-Class Antibodies in an HIV-1-Infected Chinese Donor. Immunity (2016) 0.85
HIV-1 Env gp120 structural determinants for peptide triazole dual receptor site antagonism. Proteins (2012) 0.85
Elicitation of HIV-1-neutralizing antibodies against the CD4-binding site. Curr Opin HIV AIDS (2013) 0.85
Antibody neutralization and escape by HIV-1. Nature (2003) 21.48
Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science (1994) 13.54
The antigenic structure of the HIV gp120 envelope glycoprotein. Nature (1998) 12.44
Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature (2007) 11.73
Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS. Cell (1986) 10.70
HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature (2002) 9.62
Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature (2009) 9.51
Molecular architecture of native HIV-1 gp120 trimers. Nature (2008) 8.04
Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol (2008) 7.14
Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med (2007) 7.12
A soluble form of CD4 (T4) protein inhibits AIDS virus infection. Nature (1988) 6.39
Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol (2008) 5.69
Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J Virol (2003) 5.59
Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. Structure (2000) 5.57
Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J Virol (2008) 4.73
Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol (2007) 4.45
Energetics of the HIV gp120-CD4 binding reaction. Proc Natl Acad Sci U S A (2000) 4.44
Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol (2005) 4.35
An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection. J Immunol (1991) 3.99
Conformational selection or induced fit: a flux description of reaction mechanism. Proc Natl Acad Sci U S A (2009) 3.03
Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin. J Virol (2002) 2.91
Selective recognition of oligomeric HIV-1 primary isolate envelope glycoproteins by potently neutralizing ligands requires efficient precursor cleavage. Virology (2005) 2.86
Probability analysis of variational crystallization and its application to gp120, the exterior envelope glycoprotein of type 1 human immunodeficiency virus (HIV-1). J Biol Chem (1999) 2.85
Molecular profile of an antibody response to HIV-1 as probed by combinatorial libraries. J Mol Biol (1993) 2.42
Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules. Nature (1989) 2.17
Biochemical and biological characterization of a dodecameric CD4-Ig fusion protein: implications for therapeutic and vaccine strategies. J Biol Chem (2002) 1.79
Development of an HIV-1 reference panel of subtype B envelope clones isolated from the plasma of recently infected individuals. J Acquir Immune Defic Syndr (2007) 1.27
Structure of the Fab fragment of F105, a broadly reactive anti-human immunodeficiency virus (HIV) antibody that recognizes the CD4 binding site of HIV type 1 gp120. J Virol (2005) 1.10
Automation of protein crystallization trials: use of a robot to deliver reagents to a novel multi-chamber vapor diffusion plate. Biotechniques (1989) 0.87
Antibody neutralization and escape by HIV-1. Nature (2003) 21.48
Complete replication of hepatitis C virus in cell culture. Science (2005) 18.59
The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature (2004) 17.56
HIV envelope induces a cascade of cell signals in non-proliferating target cells that favor virus replication. Proc Natl Acad Sci U S A (2002) 17.22
Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science (2009) 17.14
Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol (2005) 15.61
Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science (2010) 14.91
Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A (2005) 14.78
Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature (2007) 11.73
Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature (2011) 11.07
Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science (2010) 10.69
HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature (2002) 9.62
Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature (2009) 9.51
HIV vaccine design and the neutralizing antibody problem. Nat Immunol (2004) 9.48
Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science (2011) 9.00
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol (2004) 8.99
Evaluation of gene expression measurements from commercial microarray platforms. Nucleic Acids Res (2003) 8.08
Fc receptor but not complement binding is important in antibody protection against HIV. Nature (2007) 7.96
Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science (2011) 7.92
The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120. J Virol (2002) 7.82
Structure of a V3-containing HIV-1 gp120 core. Science (2005) 7.69
Printed covalent glycan array for ligand profiling of diverse glycan binding proteins. Proc Natl Acad Sci U S A (2004) 7.55
Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature (2011) 7.20
Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med (2007) 7.12
Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. Proc Natl Acad Sci U S A (2006) 6.82
Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science (2003) 6.68
Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA (2002) 6.59
Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature (2003) 6.35
Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med (2009) 6.14
The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol (2002) 6.11
Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. Science (2006) 6.06
Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med (2007) 6.05
Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol (2009) 5.91
Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med (2009) 5.87
Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog (2009) 5.82
Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med (2003) 5.71
Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol (2008) 5.69
Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J Virol (2003) 5.59
Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis (2006) 5.53
Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science (2013) 5.53
A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science (2011) 5.44
Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature (2012) 5.44